Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions for maintenance of acid-base balance, isotonicity, and electrophysiological function; dextrose provides calories and may restore blood glucose levels; sodium chloride maintains fluid and electrolyte balance. The combination corrects hypokalemia and dehydration.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Maintenance or replacement of potassium in patients with hypokalemia,Fluid and electrolyte replenishment in patients requiring potassium and sodium,Caloric source for patients needing dextrose
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion at a rate of up to 10 m Eq/h potassium chloride, with typical adult dose of 20-40 m Eq potassium per 1000 m L of solution (e.g., 1 L of this preparation provides 5 m Eq K+). Rate adjusted based on serum potassium and clinical status.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Potassium has a terminal elimination half-life of approximately 3-4 hours in healthy individuals, reflecting rapid renal clearance. However, redistribution and total body potassium turnover are slower (days) due to large intracellular stores. Clinical context: Half-life is prolonged in renal impairment or hypokalemia, and shortened in hyperkalemia.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose is metabolized via glycolysis and the Krebs cycle; potassium is excreted primarily by the kidneys; sodium is excreted by the kidneys and sweat.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Potassium is primarily excreted renally (90%) with minor fecal (10%) elimination. In this formulation, dextrose and sodium chloride are fully metabolized or excreted: dextrose undergoes cellular uptake and metabolism; sodium chloride is renally eliminated with sodium reabsorption and chloride as counterion.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Potassium is not significantly protein-bound (<5%). Dextrose and sodium chloride are not bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Potassium Vd is 0.5-0.7 L/kg (approximately 35-50 L in adults), reflecting predominantly intracellular distribution (>98% of body potassium is intracellular). Clinical meaning: Large Vd necessitates loading doses for repletion.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% bioavailability. Not administered orally (100% oral bioavailability for oral potassium salts, but this formulation is IV only).
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia. For GFR 30-60 m L/min, reduce infusion rate and monitor potassium closely; specific dose reduction not defined, use conservative rates (e.g., ≤5 m Eq/h).
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific Child-Pugh based dose adjustment required, but monitor serum potassium as hepatic impairment may affect potassium homeostasis. Use caution in severe hepatic failure.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Weight-based: 0.5-1 m Eq/kg per day as maintenance, rate not to exceed 0.5 m Eq/kg/h. For this solution (0.037% KCl = 5 m Eq/1000 m L), infusion rate calculated based on desired potassium dose, e.g., 2-4 m L/kg/h for maintenance (providing 0.01-0.02 m Eq/kg/h K+). Monitor serum potassium.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Elderly patients may have reduced renal function; use lower initial infusion rates (e.g., ≤5 m Eq/h) and monitor serum potassium and renal function closely. Avoid in patients with impaired renal function.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Concentrated potassium chloride solutions (not this one; this is a dilute solution) have been associated with fatalities due to maladministration; however, this product is a dilute preparation and does not carry a black box warning.
None
Use with caution in patients with severe renal impairment, cardiac disease, or hyperkalemia,Monitor serum potassium levels and renal function,Rapid infusion may cause hyperkalemia and cardiac arrhythmias,Contains dextrose; caution in patients with glucose intolerance,Not for rapid correction of severe hypokalemia
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperkalemia,Severe renal impairment (oliguria, anuria),Addison's disease,Hypersensitivity to any component
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No direct food interactions with this intravenous solution. However, patients should avoid excessive dietary potassium (bananas, oranges, tomatoes, potatoes, spinach, nuts, avocados) and salt substitutes containing potassium chloride to prevent hyperkalemia. Sodium intake may need monitoring; avoid high-sodium foods if salt restriction is indicated.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Potassium chloride, as an electrolyte supplement, has no known teratogenic risk. Dextrose and sodium chloride are physiologic. No fetal risks identified in any trimester.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Compatible with breastfeeding. Potassium, dextrose, and sodium chloride are normal components of breast milk. No M/P ratio available; levels are physiologic and not expected to cause adverse effects in infants.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No dose adjustments required specifically for pregnancy. Administer based on maternal electrolyte deficits, volume status, and glucose requirements. Increased intravascular volume in pregnancy may alter distribution, but standard clinical dosing is appropriate.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
This solution provides 0.037% potassium chloride (5.0 m Eq/L K+), 5% dextrose (50 g/L), and 0.33% sodium chloride (56 m Eq/L Na+). Use with caution in patients with renal impairment, hyperkalemia, or conditions predisposing to hyperkalemia (e.g., adrenal insufficiency, potassium-sparing diuretics). Rapid infusion may cause hyperkalemia and cardiac arrhythmias. Monitor serum potassium, glucose, and sodium levels. Not for dilution or as a vehicle for drugs incompatible with dextrose or electrolytes.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This infusion contains potassium, dextrose (sugar), and salt. It is given to correct or prevent electrolyte and fluid imbalances.,Tell your healthcare provider if you have kidney disease, diabetes, or are on a potassium-restricted or low-sodium diet.,Report any symptoms such as muscle weakness, irregular heartbeat, numbness, or tingling, which may indicate potassium imbalance.,This solution provides calories from dextrose; monitor blood glucose if you have diabetes.,Avoid consuming potassium-rich foods (bananas, oranges, potatoes, spinach) or salt substitutes without medical advice while receiving this infusion.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions for maintenance of acid-base balance, isotonicity, and electrophysiological function; dextrose provides calories and may restore blood glucose levels; sodium chloride maintains fluid and electrolyte balance. The combination corrects hypokalemia and dehydration.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is: Intravenous infusion at a rate of up to 10 m Eq/h potassium chloride, with typical adult dose of 20-40 m Eq potassium per 1000 m L of solution (e.g., 1 L of this preparation provides 5 m Eq K+). Rate adjusted based on serum potassium and clinical status.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, as an electrolyte supplement, has no known teratogenic risk. Dextrose and sodium chloride are physiologic. No fetal risks identified in any trimester.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.